Concepedia

Sergey Karakashev

SK

Statistics

Publications

10

Citations

1.1K

H-Index

10

Active since

2013

Affiliations

The Wistar Institute(Current)

University of Pennsylvania

Kazan Federal University

Moffitt Cancer Center

Drexel University

Sergey Karakashev is an author at The Wistar Institute specializing in oncology, molecular oncology, and medicine.

ORCID

Publications per year

2013–2022

10

Publications

10

N6-Methylation of Adenosine of <i>FZD10</i> mRNA Contributes to PARP Inhibitor Resistance

Takeshi Fukumoto, Hengrui Zhu, Timothy Nacarelli et al. · Cancer Research · 2019 · 191 citations · Full text

, , +17

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama et al. · Cell Reports · 2017 · 174 citations · Full text

, , +17

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

Sergey Karakashev, Takeshi Fukumoto, Bo Zhao et al. · Cancer Cell · 2020 · 153 citations · Full text

, , +16

Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma

Shuai Wu, Takeshi Fukumoto, Jianhuang Lin et al. · Nature Cancer · 2021 · 125 citations · Full text

, , +12

The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance

Kelly A. Whelan, Luciana P. Schwab, Sergey Karakashev et al. · Journal of Biological Chemistry · 2013 · 104 citations · Full text

, , +17

1–5 of 10